Who are Juvena Therapeutics's investors?

Juvena Therapeutics's investors include Alumni Ventures, Bascom Ventures, Bison Ventures, Compound, Harmonix Fund, Horizons Ventures, Manta Ray Ventures, Open Field Capital and 4 more.

How much funding has Juvena Therapeutics raised?

Juvena Therapeutics has disclosed $34.8M raised across 2 rounds.

Where is Juvena Therapeutics headquartered?

Juvena Therapeutics is headquartered in Redwood City, US.

Juvena Therapeutics

Redwood City, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 12 known investors

Find your way into Juvena Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Juvena Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.

AI & Machine Learning Biotech Longevity Medical Devices

Founders & leadership

Juvena Therapeutics was founded in 2017 by Jeremy O'Connell, PhD, Hanadie Yousef, PhD, Jeremy O'Connell, and Dr. Hanadie Yousef.

Jeremy O'Connell, PhDChief Scientific Officer and Co-Founder

Hanadie Yousef, PhDCo-Founder, Director and Executive Advisor

Jeremy O'Connell CSO and Co-founderHe holds a PhD in protein biochemistry and brings 15 years of experience in mass spectrometry-based proteomics, cell and systems biology, and various imaging techniques.

Dr. Hanadie Yousef Founder, Board Director and Executive AdvisorDr. Hanadie Yousef founded Juvena Therapeutics in 2017, serving as CEO, CFO, and Board Chair through 2025 before continuing as Board Director and Executive Advisor; the company develops biologics from human secreted proteins to treat aging-related muscle and metabolic disorders. She holds a B.S. from Carnegie Mellon and a PhD from UC Berkeley, completed postdoctoral training at Stanford School of Medicine, and also runs the advisory firm Luminous BioStrategies.

Julie Anne SmithChief Executive Officer and Director

Board

Ben Hemani Board directorFounding Partner at Bison Ventures

Laura Lande-Diner Board Member

Ayman AlAbdallahBoard director

Steven James Member Board of Directors

Stephen JuelsgaardMember Board Of Directors

Christopher KirkBoard director

Investors · 12

Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M

Bascom Ventureslisted by Bascom VenturesBoston

How we know: Bascom Ventures's portfolio page · Not right? Tell us

Bison Ventureslisted by Bison VenturesSeattle

How we know: a partner's Signal profile · funding news · businesswire.com · Not right? Tell us

Compoundlisted by CompoundNew York · $400K – $1.5M

How we know: Compound's portfolio page · the VCSheet dataset · Not right? Tell us

Harmonix Fundlisted by Harmonix FundLa Quinta

How we know: Harmonix Fund's portfolio page · Not right? Tell us

Horizons Ventureslisted by Horizons VenturesHong Kong · $500K – $10M

Manta Ray Ventureslisted by Manta Ray VenturesLondon

How we know: Manta Ray Ventures's portfolio page · Not right? Tell us

Open Field Capitallisted by Open Field CapitalNew York

Plum Alley Investmentslisted by Plum Alley InvestmentsNew York · $500K – $1.5M

How we know: Plum Alley Investments's portfolio page · the VCSheet dataset · Not right? Tell us

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

Transform Capital Managementlisted by Transform Capital ManagementSan Francisco

How we know: Transform Capital Management's portfolio page · Not right? Tell us

BoxOne VenturesreportedMontréal · $500K

How we know: the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$34.8M disclosed across 2 rounds · 2018–2025

▶$30.5MraisedJul 2025 · 12 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Steven JamesDirector
Ben HemaniDirector
Stephen JuelsgaardDirector
Hanadie YousefExecutive Officer, Director
Laura Lande-DinerDirector
Christopher KirkDirector
Ayman AlAbdallahDirector
Jeremy O'ConnellDirector

Offering amount: $41M
Amount sold: $30.5M
First sale: Jun 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.3MraisedFeb 2018 · 23 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Hanadie YousefExecutive Officer, Director

Offering amount: $4.3M
Amount sold: $4.3M
First sale: Feb 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

5 people who came through Juvena Therapeutics went on to found or lead other companies.

Laura Lande-DinerDirectorFounded Evelo Biosciences +1 Rami HannoushMember Board Of DirectorsFounded Epi Biologics Steven JamesDirectorFounded Pionyr Immunotherapeutics Stephanie MichelsenGraduate Research InternFounded Jellatech Ameet MallikStrategic AdvisorFounded ADC Therapeutics SA

Related companies · 2

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Juvena Therapeutics.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2021	$254.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Juvena Therapeutics Raises $33.5M in Series B Fundingfinsmes.com · Jan 2026

Juvena Therapeutics has filed a notice of an exempt offering of securities to raise $41 Million in New Funding. - intelligence360intelligence360.news · Sep 2025

Frequently asked questions

What does Juvena Therapeutics do?: Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.
Who founded Juvena Therapeutics?: Juvena Therapeutics was founded by Jeremy O'Connell, PhD, Hanadie Yousef, PhD, Jeremy O'Connell, Dr. Hanadie Yousef in 2017.
Who are Juvena Therapeutics's investors?: Juvena Therapeutics's investors include Alumni Ventures, Bascom Ventures, Bison Ventures, Compound, Harmonix Fund, Horizons Ventures, Manta Ray Ventures, Open Field Capital and 4 more.
How much funding has Juvena Therapeutics raised?: Juvena Therapeutics has disclosed $34.8M raised across 2 rounds.
Where is Juvena Therapeutics headquartered?: Juvena Therapeutics is headquartered in Redwood City, US.